Oncoceutics featured in Global Pheochromocytoma Pipeline Report 2019: Development Activities & Commercial Assessment
Please find the report here.
-
Our Team
Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.Learn more -
Our Science
Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.Learn more -
Alliances
Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.Learn more
In The News
-
NOV 04 2019
-
-
OCT 25 2019
Wuxi AppTec: Innovation That Matters: Interview with Lee Schalop, MD, COO of Oncoceutics
As part of an exclusive series spotlighting the inside perspectives of thought leaders on topics shaping the future of new medicines, WuXi AppTec Communications spoke with Schalop about his company’s technology and the challenges of developing new therapies for high-grade glioma patients. The full article can be found here.
-
Press Releases
Events
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.